Biocon expands Yesintek market rights across nine more markets

Regulatory Product ApprovalBusiness Updates View source PDF Explain this filing

BIOCON · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+1.6%Reaction day

₹323.50

prior close

₹323.00

announcement price

After-mkt

timing

Nifty Midcap 150market+1.1%+0.6% vs market

Pharmaceuticals peers, median of 174sector+1.2%+0.5% vs sector

On the reaction day the stock moved 0.6 pts more than Nifty Midcap 150 and 0.5 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.2

10m

-0.3

15m

+0.6

30m

+0.7

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+1.6+1.1+0.6+1.2+0.5

Next day

+2.8+2.0+0.8+3.1-0.4

+7.7pendingpending+4.7+3.0

—————

15d

—————

UpDownMarket · Nifty Midcap 150Sector · Pharmaceuticals peers, median of 174Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Biocon signed a license agreement with Janssen Sciences Ireland for Yesintek commercialization in Australia, Brazil, China, Hong Kong, Israel, Mexico, New Zealand, South Korea and Kazakhstan. This builds on access secured in the US, Europe, UK, Canada and Japan. Stelara recorded 2025 sales of $6.08 billion. Launches remain subject to regulatory approval.

Likely market impact

Expands Yesintek's potential commercial reach, but revenue will depend on regulatory approvals and launches in each market.